Overall survival with abemaciclib in early breast cancer
Adjuvant abemaciclib-ET resulted in a statistically significant and clinically meaningful improvement in OS compared with ET in patients with HR-positive, HER2-negative, node-positive, high-risk EBC. At 7 years, abemaciclib-ET continued to demonstrate a sustained IDFS and DRFS benefit.
Authors
- H.S. Rugo
- Priya Rastogi (ORCID: https://orcid.org/0000-0002-6179-6407)
- Erika Hamilton (ORCID: https://orcid.org/0000-0002-1911-0336)
- N. Harbeck
- Patrick Neven (ORCID: https://orcid.org/0000-0002-1434-9460)
- Matthew P. Goetz (ORCID: https://orcid.org/0000-0002-4383-270X)
- Roberto Hegg (ORCID: https://orcid.org/0000-0002-6453-8155)
- F Boyle
- Chiun‐Sheng Huang (ORCID: https://orcid.org/0000-0002-6557-211X)
- SM Tolaney
- Ran Wei (ORCID: https://orcid.org/0009-0007-2395-1692)
- Laura Testa (ORCID: https://orcid.org/0000-0001-6080-7429)
- M. Campone
- Ashwin Shahir
- Javier Cortés (ORCID: https://orcid.org/0000-0001-7623-1583)
- V. Guarneri
- Elżbieta Senkus (ORCID: https://orcid.org/0000-0001-6855-397X)
- Jens Huober (ORCID: https://orcid.org/0000-0002-8618-1820)
- Zhi Min Shao
- L. Del Mastro
- Montserrat Muñoz-Mateu (ORCID: https://orcid.org/0000-0001-7772-1437)
- S. Johnston
- María Ángeles Martín (ORCID: https://orcid.org/0000-0001-8173-4521)
- J. O’Shaughnessy
- Belén San Antonio
- J. Sohn
Institutions
- Centre National de la Recherche Scientifique (FR)
- The University of Sydney (AU)
- Royal Marsden NHS Foundation Trust (GB)
- Inserm (FR)
- Eli Lilly (United States) (US)
- Yonsei University (KR)
- Kantonsspital St. Gallen (CH)
- Texas Oncology (US)
- Baylor University Medical Center (US)
- Hospital General Universitario Gregorio Marañón (ES)
- Fudan University Shanghai Cancer Center (CN)
- Sarah Cannon (US)
- D’Or Institute for Research and Education (BR)
- Institut de Cancérologie de l'Ouest (FR)
- Istituto Oncologico Veneto (IT)
- Olgahospital (DE)
- Dana-Farber Cancer Institute (US)
- Istinye University (TR)
- Mayo Clinic in Arizona (US)
- UPMC Hillman Cancer Center (US)
- National Taiwan University Hospital (TW)
- Ospedale Policlinico San Martino (IT)
- Mayo Clinic in Florida (US)
- International Breast Cancer Study Group (CH)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- NSABP Foundation (US)
- GEICAM – Spanish Breast Cancer Group (ES)
- Centro de Pesquisas Oncológicas (BR)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- Gdańsk Medical University (PL)
- Ludwig-Maximilians-Universität München (DE)
- Nantes Université (FR)
- KU Leuven (BE)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1016/j.annonc.2025.10.005
- Citations
- 9
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 13.67
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Ariad Pharmaceuticals
- Celgene
- Genomic Health
- Helsinn
- Queen Mary University of London
- Baxalta
- Exelixis
- Jazz Pharmaceuticals
- Les Laboratories Pierre Fabre
- Clovis Oncology
- Mylan
- Mersana Therapeutics
- BeiGene
- Incyte
- Carrick Therapeutics
- Puma Biotechnology
- G1 Therapeutics
- Seagen
- Natera
- National Institute for Health and Care Research
- Eisai
- Max-Planck-Gesellschaft
- Servier
- Ipsen
- Aptitude Health
- Genentech
- Samsung
- Helsinn Therapeutics
- Chugai Pharmaceutical
- Loxo Oncology
- Daiichi Sankyo Europe